BasmiFIP Study: Dual Antiviral Therapy Achieves 78.3% Remission in 46 Cats with Feline Infectious Peritonitis (FIP), Including Drug-Resistant Cases
- BasmiFIP India
- 9 hours ago
- 5 min read
Field evaluation results show combined oral GS-441524 and EIDD-1931 works in real-world conditions, with a notably low 6.5% relapse rate even in cats that had previously failed single-drug treatment.
A Comprehensive Look at the Data
When evaluating any Feline Infectious Peritonitis (FIP) treatment, the questions that matter most are straightforward: how many cats recovered, how many relapsed, what were the side effects, and did it work for the difficult cases? The 2024 BasmiFIP field evaluation by Li and Cheah provides clear answers to all of these.
This study is particularly valuable because it did not limit enrollment to first-time treatment cases. A significant subset of the 46 cats had already relapsed after completing GS-441524 monotherapy, meaning the virus had already demonstrated some degree of drug resistance. Evaluating a dual antiviral protocol in this challenging population provides stronger evidence than studying only easy first-time cases.
Study Design
Between June and September 2024, 46 domestic cats diagnosed with Feline Infectious Peritonitis (FIP) were enrolled under the BasmiFIP initiative. The cohort encompassed all Feline Infectious Peritonitis (FIP) phenotypes: wet (effusive), dry (non-effusive), neurological, and ocular. Various breeds and ages were represented. Approximately 90% were indoor-only cats.
Each cat received a co-formulated oral capsule containing GS-441524 (10-15 mg/kg once daily) and EIDD-1931 (5 mg for cats under 4.5 kg, or 10 mg/kg for cats 4.5 kg and above). Treatment duration was 60 days, with one capsule per 2.5 kg of body weight every 24 hours.
Owners submitted daily tracking data including weight, appetite, clinical signs, and side effects. Veterinary validation was obtained where possible. All cats were followed for 180 days post-treatment completion to monitor for relapse.
Results: The Numbers
Remission rate: 78.3%. 36 of the 46 cats achieved full clinical remission after the 60-day dual antiviral protocol. Complete absence of Feline Infectious Peritonitis (FIP) symptoms following treatment.
Relapse rate: 6.5%. Only 3 cats experienced a return of Feline Infectious Peritonitis (FIP) symptoms during the 180-day follow-up period. This is notably lower than the approximately 10-11% relapse rate reported in published GS-441524 monotherapy studies, which evaluate first-time treatment populations.
Mortality: 10.9%. 5 cats did not survive. The authors attributed these outcomes primarily to advanced disease stages or secondary complications present when treatment began. This reinforces the critical importance of starting treatment early, before the disease progresses beyond the point where even combination therapy can help.
Weight and appetite recovery: 91%. By mid-treatment, 42 of the 46 cats demonstrated documented weight gain and appetite improvement through individual daily logs. Consistent weight recovery during antiviral treatment is one of the strongest clinical indicators that the virus is being successfully suppressed.
A:G ratio trajectory. The albumin-to-globulin ratio, a key blood marker for tracking Feline Infectious Peritonitis (FIP) disease activity and treatment response, showed progressive improvement throughout the study. From a baseline of approximately 0.35, the mean A:G ratio rose to approximately 0.45 by Day 30 and reached 0.62 by Day 60. This steady upward trajectory indicates that the systemic inflammatory response driven by the Feline Infectious Peritonitis (FIP) virus was actively resolving during the course of dual antiviral therapy.
Adverse events: minimal. Only 2 of the 46 cats experienced side effects: minor gastrointestinal issues and brief lethargy during the early dosing period. Both resolved without intervention. No severe toxicity was observed at any point. No cat had to discontinue treatment due to adverse effects.
Interpreting the 78.3% Remission Rate
A 78.3% remission rate requires context to interpret properly. The approximately 92% success rate commonly cited for GS-441524 treatment comes from studies evaluating cats receiving antiviral therapy for the first time. The BasmiFIP study population was fundamentally different: a significant proportion of enrolled cats had already completed and relapsed after GS-441524 monotherapy.
Treating drug-resistant Feline Infectious Peritonitis (FIP) is inherently more difficult than treating naive cases. The virus in these cats has already survived a full course of GS-441524, suggesting it has acquired some capacity to evade chain termination. Achieving 78.3% remission in this harder population is a clinically meaningful result.
The 6.5% relapse rate is arguably the most significant finding. In first-time GS-441524 monotherapy studies, approximately 10-11% of cats relapse. This study achieved a lower relapse rate in a more difficult patient population. The implication is that the dual mechanism of GS-441524 (chain termination) combined with EIDD-1931 (lethal mutagenesis) provides more durable viral suppression than either drug alone.
The Pharmacological Logic Behind the Results
The dual protocol works because GS-441524 and EIDD-1931 attack the Feline Infectious Peritonitis (FIP) virus through entirely different mechanisms.
GS-441524 directly blocks viral replication by terminating the RNA chain during the copying process. The virus cannot produce new copies of itself.
EIDD-1931 takes the opposite approach. Instead of stopping copies from being made, it corrupts whatever copies the virus does manage to produce. It introduces errors into the viral genetic code that accumulate with each replication cycle until the genome becomes completely nonfunctional. The virus destroys itself through its own defective copies, a process known as lethal mutagenesis.
When both mechanisms operate simultaneously, the virus faces a dual evolutionary challenge. To survive the treatment, it would need to develop resistance against both chain termination and lethal mutagenesis at the same time. The statistical probability of this occurring is substantially lower than developing resistance to either mechanism alone, which explains why the dual protocol showed particular effectiveness in cats where single-drug resistance had already been established.
What This Means for Cat Owners in India
If your cat has been diagnosed with Feline Infectious Peritonitis (FIP), this study provides practical, real-world evidence that dual antiviral therapy is effective, safe, and manageable:
It works for the hardest cases. Even cats that had already relapsed on GS-441524 monotherapy showed strong recovery rates with the dual protocol. If your cat has relapsed or is not responding to single-drug treatment, this study supports that combination therapy can still achieve remission.
Relapse is rare. At just 6.5% over 180 days, the dual protocol demonstrated strong durability against viral recurrence, even in a population where the virus had already shown resistance characteristics.
Side effects are minimal. Only 2 minor events across 46 cats, with no treatment discontinuations. The combined oral capsule is well-tolerated throughout the full 60-day treatment course.
One capsule per day. No injections. No complex multi-drug dosing schedules. The single daily oral capsule format makes treatment practical for home administration, even for cat owners managing Feline Infectious Peritonitis (FIP) treatment for the first time.
Early treatment remains essential. The mortality in this study was concentrated among cats with the most advanced disease at enrollment. Starting treatment promptly, whether it is a first diagnosis or a relapse, remains the single most important factor in determining outcomes.
Study Limitations
The authors acknowledge that this was an observational field study, not a randomized controlled trial. There was no control group, and some outcome data relied on owner reports. Pharmacokinetic studies and randomized comparative trials are needed to further substantiate these findings. However, the real-world conditions, diverse Feline Infectious Peritonitis (FIP) phenotypes, and deliberate inclusion of previously relapsed cats make this evaluation a valuable and practical contribution to the growing evidence base for combination antiviral therapy.
Read the Full Study
Want to dive deeper into the methodology, data, and clinical analysis? Download or read the complete research paper.
"Enhancing FIP Therapeutic Outcomes: A Field-Based Evaluation of Combined Oral GS-441524 and EIDD-1931 Protocols" by Li, Y. & Cheah, B. (2024). BasmiFIP Initiative.
For more information or to consult about your cat's treatment plan, visit basmifipindia.com or contact the BasmiFIP India team via WhatsApp.
Free consultations available. Because when every day counts, having the right support makes all the difference.
Reference: Li, Y. & Cheah, B. (2024). Enhancing FIP Therapeutic Outcomes: A Field-Based Evaluation of Combined Oral GS-441524 and EIDD-1931 Protocols. BasmiFIP Initiative.
Comments